Document is current

Any future updates will be listed below

Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

Crossref DOI link: https://doi.org/10.1038/s41467-023-40050-1

Published Online: 2023-07-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark